Summary of findings 2. PRO 140 compared to placebo for treatment of people with HIV infection.
| PRO 140 compared to placebo for treatment of people with HIV infection | ||||||
| Patient or population: patients being treated for HIV infection Intervention: PRO 140 Comparison: placebo | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Placebo | PRO 140 | |||||
| Individual nadir changes in HIV‐1 RNA level: 0.5 mg/kg | The mean individual nadir changes in HIV‐1 RNA level: 0.5 mg/kg in the control groups was ‐0.39 copies/mL | The mean individual nadir changes in HIV‐1 RNA level: 0.5 mg/kg in the intervention groups was 0.19 lower (0.42 lower to 0.04 higher) | 19 (1 study) | ⊕⊝⊝⊝ very low1,2 | ||
| Individual nadir changes in HIV‐1 RNA level: 2 mg/kg | The mean individual nadir changes in HIV‐1 RNA level: 2 mg/kg in the control groups was ‐0.39 copies/mL | The mean individual nadir changes in HIV‐1 RNA level: 2 mg/kg in the intervention groups was 0.81 lower (1.22 to 0.4 lower) | 19 (1 study) | ⊕⊝⊝⊝ very low1,2 | ||
| Individual nadir changes in HIV‐1 RNA level: 5 mg/kg | The mean individual nadir changes in HIV‐1 RNA level: 5mg/kg in the control groups was ‐0.305 copies/mL | The mean individual nadir changes in HIV‐1 RNA level: 5 mg/kg in the intervention groups was 1.49 lower (1.65 to 1.32 lower) | 40 (2 studies) | ⊕⊝⊝⊝ very low1,2 | ||
| Individual nadir changes in HIV‐1 RNA level: 10 mg/kg | The mean individual nadir changes in HIV‐1 RNA level: 10 mg/kg in the control groups was ‐0.32 copies/mL | The mean individual nadir changes in HIV‐1 RNA level: 10 mg/kg in the intervention groups was 1.51 lower (1.8 to 1.22 lower) | 21 (1 study) | ⊕⊝⊝⊝ very low1,2 | ||
| Individual nadir changes in HIV‐1 RNA level: 162 mg weekly | The mean individual nadir changes in HIV‐1 RNA level: 162 mg weekly in the control groups was ‐0.23 copies/mL | The mean individual nadir changes in HIV‐1 RNA level: 162 mg weekly in the intervention groups was 0.76 lower (1.14 to 0.38 lower) | 21 (1 study) | ⊕⊝⊝⊝ very low1,2 | ||
| Individual nadir changes in HIV‐1 RNA level: 324 mg weekly | The mean individual nadir changes in HIV‐1 RNA level: 324 mg weekly in the control groups was ‐0.23 copies/mL | The mean individual nadir changes in HIV‐1 RNA level: 324 mg weekly in the intervention groups was 1.42 lower (1.8 to 1.04 lower) | 21 (1 study) | ⊕⊝⊝⊝ very low1,2 | ||
| Individual nadir changes in HIV‐1 RNA level: 324 mg biweekly | The mean individual nadir changes in HIV‐1 RNA level: 324 mg biweekly in the control groups was ‐0.23 copies/mL | The mean individual nadir changes in HIV‐1 RNA level: 324 mg biweekly in the intervention groups was 1.14 lower (1.67 to 0.61 lower) | 22 (1 study) | ⊕⊝⊝⊝ very low1,2 | ||
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Randomization: method not specified; Allocation concealment: unclear; Blinding: method not specified. 2 Total population size is less than 400.